Insulin-like growth factor-I and the liver

Liver International

Volumn 31, Issue 7, 2011, Pages 911-919

  Bonefeld, Karen ^a   Møller, Søren ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chronic liver disease; Cirrhosis; Growth hormone; Insulin like growth factor; Malnutrition

Indexed keywords

GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

AMINO ACID SEQUENCE; CHRONIC LIVER DISEASE; DOWN REGULATION; FIBROGENESIS; GENE THERAPY; GENE TRANSFER; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER PROTECTION; LIVER TRANSPLANTATION; MALNUTRITION; NONHUMAN; OSTEOPENIA; PROTEIN DEFICIENCY; PROTEIN STRUCTURE; REVIEW; SOMATOMEDIN C DEFICIENCY; UPREGULATION;

AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; GENE THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER DISEASES; MOLECULAR SEQUENCE DATA;

EID: 79960084386     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02428.x     Document Type: Review

References (61)

1. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13: 113-70.
2. Clifford J, Rosen MP. Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab 1999; 10: 136-41.
3. Salmon WD, Daughaday WH. A hormonally controlled serum factor which stimulates sulphate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825-36.
4. Daughaday WH. Endocrinology - the way we were: a personal history of somatomedin. Growth Horm IGF Res 2006; 16 (Suppl. A): S3-S5.
5. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10: 68-91.
6. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-76.
7. Breuhahn K, Schirmacher P. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1690-8.
8. Lann D, LeRoith D. The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 371-9.
9. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: 461-8.
10. Jenkins PJ, Frajese V, Jones AM, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000; 85: 3218-21.
11. Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996; 28: 619-37.
12. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-87.
13. Ferry RJ Jr, Cerri RW, Cohen P. Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res 1999; 51: 53-67.
14. Smith RG, Jiang H, Sun Y. Developments in ghrelin biology and potential clinical relevance. Trends Endocrinol Metab 2005; 16: 436-42.
15. Lengyel AM. Novel mechanisms of growth hormone regulation: growth hormone-releasing peptides and ghrelin. Braz J Med Biol Res 2006; 39: 1003-11.
16. Fanciulli G, Delitala A, Delitala G. Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone. Hum Reprod Update 2009; 15: 341-58.
17. Giordano R, Bonelli L, Marinazzo E, et al. Growth hormone treatment in human ageing: benefits and risks. Hormones 2008; 7: 133-9.
18. Kondrup J, Nielsen K, Juul A. Effect of long-term refeeding on protein metabolism in patients with cirrhosis of the liver. Br J Nutr 1997; 77: 197-212.
19. Holland-Fischer P, Vilstrup H, Frystyk J, et al. The IGF system after insertion of a transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis. Eur J Endocrinol 2009; 160: 957-63.
20. Figueiredo FA, De Mello PR, Kondo M. Effect of liver cirrhosis on body composition: evidence of significant depletion even in mild disease. J Gastroenterol Hepatol 2005; 20: 209-16.
21. Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 1995; 103: 63-74.
22. Kalaitzakis E, Bosaeus I, Ohman L, Bjørnsson E. Altered postprandial glucose, insulin, leptin, and ghrelin in liver cirrhosis: correlations with energy intake and resting energy expenditure. Am J Clin Nutr 2007; 85: 808-15.
23. Shankar TP, Fredi JL, Himmelstein S, et al. Elevated growth hormone levels and insulin resistance in patients with cirrhosis of the liver. Am J Med Sci 1986; 291: 248-54.
24. Cuneo RC, Hickman PE, Wallace JD, et al. Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocrinol 1995; 43: 265-75.
25. Salerno F, Locatelli V, Muller EE. Growth hormone hyperresponsiveness to growth hormone-releasing hormone in patients with severe liver cirrhosis. Clin Endocrinol 1987; 27: 183-90.
26. Muggeo M, Tiengo A, Fedele D, Crepaldi G. Altered control of growth hormone secretion in patients with cirrhosis of the liver. Arch Intern Med 1979; 139: 1157-60.
27. Assy N, Pruzansky Y, Gaitini D, et al. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 2008; 49: 34-42.
28. Clemmons DR, Klibanski A, Underwood LE, et al. Reduction of plasma immunoreactive somatomedin C during fasting in humans. J Clin Endocrinol Metab 1981; 53: 1247-50.
29. Mohan PS, Jaya Rao KS. Plasma somatomedin activity in protein calorie malnutrition. Arch Dis Child 1979; 54: 62-4.
30. Frystyk J, Ivarsen P, Skjærbæk C, et al. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999; 56: 2076-84.
31. Cuneo RC, Hickman PE, Wallace JD, et al. Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocrinol 1995; 43: 265-75.
32. Donaghy A, Ross R, Wicks C, et al. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology 1997; 113: 1617-22.
33. Assy N, Hochberg Z, Amit T, et al. Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J Hepatol 1997; 27: 796-802.
34. Wu YL, Ye J, Zhang S, et al. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 2004; 10: 2740-3.
35. Shen XY, Holt RI, Miell JP, et al. Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors. J Clin Endocrinol Metab 1998; 83: 2532-8.
36. LeRoith D, Adamo ML, Shemer J, et al. Retinoic acid inhibits growth of breast cancer cell lines: the role of insulin-like growth factor binding proteins. Growth Regul 1993; 3: 78-80.
37. Donaghy AJ, Delhanty PJ, Ho KK, et al. Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol 2002; 36: 751-8.
38. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
39. Propst T, Propst A, Herold M, et al. Spontaneous bacterial peritonitis is associated with high levels of interleukin-6 and its secondary mediators in ascitic fluid. Eur J Clin Invest 1993; 23: 832-6.
40. De BF, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643-50.
41. Møller S, Juul A, Becker U, et al. Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis. J Clin Endocrinol Metab 1995; 80: 1148-57.
42. Schimpff RM, Lebrec D, Dannadieu M, Repellin AM. Serum somatomedin activity measured as sulphation factor in peripheral, hepatic and renal veins of patients with alcoholic cirrhosis. Acta Endocrinol 1978; 88: 729-36.
43. Ohlsson C, Mohan S, Sjogren K, et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009; 30: 494-535.
44. Jeyaratnaganthan N, Grønbæk H, Holland-Fischer P, et al. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum. Clin Endocrinol 2010; 72: 625-32.
45. Goral V, Simsek M, Mete N. Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol 2010; 16: 1639-43.
46. George J, Ganesh HK, Acharya S. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009; 15: 3516-22.
47. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28: 695-9.
48. Wu YL, Ye J, Zhang S, et al. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 2004; 10: 2740-3.
49. Volzke H, Nauck M, Rettig R, et al. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol 2009; 161: 705-13.
50. De Palo EF, Bassanello M, Lancerin F, et al. GH/IGF system, cirrhosis and liver transplantation. Clin Chim Acta 2001; 310: 31-7.
51. Møller S, Becker U, Grønbæk M, et al. Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. J Hepatol 1994; 21: 710-7.
52. Wallace JD, Abbott-Johnson WJ, Crawford DH, et al. GH treatment in adults with chronic liver disease: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 2002; 87: 2751-9.
53. Blaas L, Kornfeld JW, Schramek D, et al. Disruption of the growth hormone-signal transducer and activator of transcription 5-insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology 2010; 51: 1319-26.
54. Sobrevals L, Rodriguez C, Romero-Trevejo JL, et al. Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 2010; 51: 912-21.
55. Conchillo M, Prieto J, Quiroga J. Insulin-like growth factor I (IGF-I) and liver cirrhosis. Rev Esp Enferm Dig 2007; 99: 156-64.
56. Conchillo M, de Knegt RJ, Payeras M, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005; 43: 630-6.
57. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 35: 685-93.
58. Smedile A, Bugiansi E. Statosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci 2005; 9: 291-3.
59. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
60. Vera M, Sobrevals L, Zaratiegui M, et al. Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis. Gene Ther 2007; 14: 203-10.
61. Arad U, Zeira E, El-Latif MA, et al. Liver-targeted gene therapy by SV40-based vectors using the hydrodynamic injection method. Hum Gene Ther 2005; 16: 361-71.